A federal outside panel voted Thursday to soften rules on seven peptides, including BPC-157 and TB-500. The vote was narrow. It is not final. The FDA has given no signal on whether it will take up the recommendation. The move came after weeks of stakeholder sessions. Wellness backers pressed firmly for wider access. RFK Jr. was among them. Critics say these compounds have no real proof of safety or help for most uses. The call could change how the agency handles a part of the wellness market that is expanding rapidly. Regulators are watching to see if the agency takes up the plan. A representative for the agency offered no clear schedule for a next move. Backers argue the change would widen access to substances some say help. Skeptics warn that looser rules could weaken safeguards across a fast-moving market. The committee vote only clears a path to a change, and the final decision rests with the federal regulator.